Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07539090 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Phase 1 study, sponsored by Deciphera Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07539090 is a Phase 1 study that is actively recruiting participants, run by Deciphera Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT07539090, a Phase 1 study, is actively recruiting participants, sponsored by Deciphera Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of combined oral contraceptive (COC) (ethinyl estradiol/levonorgestrel) in healthy female participants. This study will last approximately 35 days.
Interventions
- DRUG Vimseltinib
- DRUG Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG])
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-06-05 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07539090
The ClinicalTrials.gov registry entry for NCT07539090 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Deciphera Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vimseltinib is the first listed.
NCT07539090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07539090 about?
NCT07539090 is a clinical study titled "Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)". The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of combined oral contraceptive (COC) (ethinyl estradiol/levonorgestrel) in healthy female participants. This study will last approximately 35 days.
What is the current status of trial NCT07539090?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-06-05. Estimated completion is 2026-08.
What interventions are being tested in trial NCT07539090?
The interventions under investigation include: Vimseltinib (DRUG), Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG]) (DRUG).
Who is sponsoring clinical trial NCT07539090?
This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.